| Autor: |
Hai-Jun Wen, Pei Lin, Gong-Xun Zhong, Zhi-Chao Xu, Lei Shuai, Zhi-Yuan Wen, Chong Wang, Xue Cao, Wen-Bin He, Jing Feng, Qi-Chun Cai, Hua-Juan Ma, Si-Jin Wu, Guo-Dong Wang, Xue-Mei Lyu, Feng-Liang Liu, Yong-Tang Zheng, Hui Zeng, Xiong-Lei He, Hualan Chen, Fu-Jie Zhang, Chung-I Wu |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.04.16.440104 |
| Popis: |
In the search for treatment schemes of COVID-19, we start by examining the general weakness of coronaviruses and then identify approved drugs attacking that weakness. The approach, if successful, should identify drugs with a specific mechanism that is at least as effective as the best drugs proposed and are ready for clinical trials. All coronaviruses translate their non-structural proteins (∼16) in concatenation, resulting in a very large super-protein. Homo-harringtonine (HHT), which has been approved for the treatment of leukemia, blocks protein elongation very effectively. Hence, HHT can repress the replication of many coronaviruses at the nano-molar concentration. In two mouse models, HHT clears SARS-CoV-2 in 3 days, especially by nasal dripping of 40 ug per day. We also use dogs to confirm the safety of HHT delivered by nebulization. The nebulization scheme could be ready for large-scale applications at the onset of the next epidemics. For the current COVID-19, a clinical trial has been approved by the Ditan hospital of Beijing but could not be implemented for want of patients. The protocol is available to qualified medical facilities. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
